Method for removing undifferentiated pluripotent stem cells
A stem cell, undifferentiated technology, applied in the field of preparing differentiated cells, undifferentiated pluripotent stem cells, and removing undifferentiated pluripotent stem cells, can solve the problems of PSCs without research and investigation drugs
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment
[0123] An important safety consideration for the use of human pluripotent stem cells (hPSCs) is the risk of tumorigenesis, as these cells can form teratomas at ectopic sites after in vivo injection. Thousands of undifferentiated hPSCs are sufficient to induce teratomas in mouse models. Therefore, it is critical to remove all residual undifferentiated hPSCs with teratoma potential prior to the clinical use of hPSC-derived cells. In the present study, the inventors' data demonstrate the cytotoxic effects of cardiac glycosides, such as digitonin, lanatoside C, bufalin, proscalin, in undifferentiated human embryonic stem cells (hESCs). Original A, digitoxin, digitoxin, and ouabain. This phenomenon was not observed in human bone marrow mesenchymal stem cells (hBMMSCs). Most importantly, digitonin and lanatoside C did not affect the differentiation ability of stem cells. Consistently, the viability of hESC-derived MSCs, neurons, endothelial cells, and endoderm of hepatocytes was ...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 


